公司概覽
業務類別 Biotechnology
業務概覽 Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.
公司地址 3611 Valley Centre Drive, Suite 300, San Diego, CA, USA, 92130
電話號碼 +1 888 969-7879
傳真號碼 --
公司網頁 https://www.travere.com
員工數量 497
 
公司高管 / 董事會成員
公司高管
高管 職務 年薪 更新日期
Ms. Elizabeth E. Reed Chief Legal Officer, General Counsel and Corporate Secretary -- 06/04/2026
Dr. William E. Rote, PhD Chief Research Officer 美元 522.33K 16/06/2026
Dr. Eric M. Dube, PhD Director, President and Chief Executive Officer 美元 854.25K 21/09/2026
Mr. Peter Heerma Chief Commercial Officer 美元 527.92K 06/04/2026
Ms. Sandra Calvin Senior Vice President and Chief Accounting Officer -- 09/07/2026
Dr. Jula Inrig, M.D. Executive Vice President, Head of Research & Development and Chief Medical Officer 美元 568.08K 16/06/2026
Mr. Christopher Cline Chief Financial Officer 美元 522.92K 06/04/2026
Mr. John Torell Vice President and Controller -- 09/07/2026
 
董事會成員
董事會 職務 更新日期
Mr. Gary A. Lyons Chairman of the Board 06/04/2026
Mr. Ron Squarer Independent Director 06/04/2026
Mr. Timothy P. Coughlin Independent Director 06/04/2026
Mr. John A. Orwin, M.B.A. Independent Director 06/04/2026
Dr. Suzanne L. Bruhn, PhD Independent Director 06/04/2026
Mr. Jeffrey A. Meckler Independent Director 06/04/2026
Ms. Sandra E. Poole Independent Director 06/04/2026
Dr. Roy D. Baynes, M.D.,PhD Independent Director 06/04/2026
Dr. Eric M. Dube, PhD Director, President and Chief Executive Officer 21/09/2026
Ms. Ruth Williams-Brinkley Independent Director 06/04/2026
 
所屬ETF (更新日期: 14/11/2026 03:27)
代號 名稱 佔比% ▼ 持有日期
BRNYBurney U.S. Factor Rotation ETF0.09%30/10/2026
FNXFirst Trust Mid Cap Core AlphaDEX® ETF0.09%29/10/2026
FTXHFirst Trust Nasdaq Pharmaceuticals ETF0.09%29/10/2026
FNYFirst Trust Mid Cap Growth AlphaDEX® ETF0.07%29/10/2026
FSMDFidelity Small-Mid Multifactor ETF0.07%30/10/2026
GSSCGoldman Sachs ActiveBeta® US SmCp Eq ETF0.06%30/10/2026
DFASDimensional US Small Cap ETF0.06%02/10/2026
SCHBSchwab US Broad Market ETF0.06%31/10/2026
PRFZInvesco RAFI US 1500 Small-Mid ETF0.05%30/10/2026
SMLFiShares U.S. Small-Cap Eq Fac ETF0.05%30/10/2026
VFMOVanguard US Momentum Factor ETF0.05%30/09/2026
FHLCFidelity MSCI Health Care ETF0.04%30/10/2026
ESMLiShares ESG Aware MSCI USA Small-Cap ETF0.04%30/10/2026
DFUSDimensional US Equity Market ETF0.04%30/10/2026
OMFSInvesco Russell 2000® Dynamic Mltfct ETF0.04%30/10/2026
BBPVirtus Biotech ETF0.04%30/10/2026
ISCGiShares Morningstar Small-Cap Growth ETF0.03%30/10/2026
BBSCJPMorgan BetaBuilders US Sml Cp Eq ETF0.03%30/10/2026
DFACDimensional US Core Equity 2 ETF0.03%02/10/2026
DWASInvesco Dorsey Wright SmallCap Momt ETF0.03%30/10/2026
  1   2    3    4    5    6  
 

Copyright © 2026 ET Net Limited.
All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.